Search

CMSC Abstracts View

Search Accepted Abstracts
Sending

Search Results

Year ID Type Category Title Authors
2023 DMT01 Platform/Oral Disease Modifying Therapies

A Retrospective Study on the Effects of De-Escalation of Disease Modifying Therapy in Patients with Multiple Sclerosis

Carolyn H Goldschmidt, DO, Northshore University Healthsystem, Evanston, IL, Jordan Glassman, DO, Touro University College of Osteopathic Medicine, Henderson, NV, Brandon Ly, DO, Touro University College of Osteopathic Medicine,, Henderson, NV, Tucker Harvey, MS, Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH and Le H Hua, MD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV

2023 DMT02 Platform/Oral Disease Modifying Therapies

Ublituximab Is Associated with Significant Improvement in Fatigue: Results from Ultimate I and II

Enrique Alvarez, MD1, Derrick Robertson, MD2, Daniel Wynn, MD3, Yihuan Xu, PhD4, Lily Lee, PhD4 and Sibyl Wray, MD5, (1)University of Colorado Anschutz Medical Campus, Aurora, CO, (2)Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, (3)Consultants in Neurology MS Center, Northbrook, IL, (4)TG Therapeutics, New York, NY, (5)Hope Neurology MS Center, Knoxville, TN

2023 DMT03 Platform/Oral Disease Modifying Therapies

Long-Term Efficacy of Ozanimod By Age Category in Patients with Relapsing Multiple Sclerosis in Two Phase 3 Trials and an Open-Label Extension Trial

Bruce A.C. Cree, MD1, Krzysztof W. Selmaj, MD, PhD, DSc2, Lawrence Steinman, MD3, Giancarlo Comi, MD4, Amit Bar-Or, MD5, Douglas L. Arnold, MD6, Hans-Peter Hartung, MD, FRCP, FEAN, FAAN, FANA7, Xavier Montalban, MD, PhD8, Eva Havrdova, MD, PhD9, James K. Sheffield, MD MBA MSMD10, Chun-Yen Cheng, MS10, Jon V. Riolo, MD10, Diego Silva, MD10, Ludwig Kappos, MD11 and Jeffrey A. Cohen, MD12, (1)Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, (2)Center for Neurology, Lodz, Poland, and Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland, (3)Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, (4)Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy, (5)Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (6)NeuroRx Research and Montreal Neurological Institute, McGill University, Montreal, QC, Canada, (7)Department of Neurology, Palacky University Olomouc, Olomouc, Czech Republic, (8)Department of Neurology-Neuroimmunology, Centre d’Esclerosi Multiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain, (9)Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic, (10)Bristol Myers Squibb, Princeton, NJ, (11)Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, (12)Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH

2023 DMT04 Platform/Oral Disease Modifying Therapies

Clinical Outcomes with Evobrutinib in Relapsing Multiple Sclerosis over 3.5 Years of Treatment: An Ongoing Phase 2 Open-Label Extension

Xavier Montalban, MD, PhD, Department of Neurology-Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain, Douglas L. Arnold, MD, Montreal Neurological Institute, Montreal, QC, Canada; NeuroRx Research, Montreal, QC, Canada, Martin S Weber, MD, Institute of Neuropathology and Department of Neurology, University Medical Center, University of Göttingen, Göttingen, Germany, Karolina Piasecka-Stryczynska, PhD, Department of Neurology and Cerebrovascular Diseases, Poznań University of Medical Sciences, Poznań, Poland, Davorka Tomic, PhD, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, Eysins, Switzerland, Anastasiia Kinkolykh, MD, Quartesian (a Veranex company), Princeton, NJ, Ying Li, MS, EMD Serono, Billerica, MA, Hans Guehring, MD, The healthcare business of Merck KGaA, Darmstadt, Germany, Enrique Alvarez, MD, PhD, MSCI, Department of Neurology, Rocky Mountain Multiple Sclerosis Center at the University of Colorado, Aurora, CO; Department of Neurology, University of Colorado, Aurora, CO and Jerry S Wolinsky, MD, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX

2023 DMT05 Platform/Oral Disease Modifying Therapies

Long-Term Efficacy of Satralizumab in Adults with Aquaporin-4-IgG-Seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon

Anthony Traboulsee, MD1, Ingo Kleiter, MD, DM2, Jacqueline Palace, DM3, Kazuo Fujihara, MD4, Albert Saiz, MD, PhD5, Ivana Vodopivec, MD, PhD6, Gaelle Klingelschmitt, MSc6, Carole Marcillat, PharmD6 and Jeffrey L Bennett, MD, PhD7, (1)University of British Columbia, Vancouver, BC, Canada, (2)Ruhr University Bochum, Bochum, Germany, (3)John Radcliffe Hospital, Oxford, United Kingdom, (4)Fukushima Medical University School of Medicine, Fukushima, Japan, (5)Service of Neurology, Hospital Clinic and Institut d’Investigacio Biomedica August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain, (6)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (7)University of Colorado School of Medicine, Aurora, CO

2023 DMT06 Platform/Oral Disease Modifying Therapies

B Cell Subsets in Multiple Sclerosis Patients Return to Healthy Control Composition Following Cessation of Ocrelizumab

Cody Gurski, BS1, Zivar Hajiyeva, MD, Ph.D.1, Kaylan Fenton, APNP2, Samantha O’Dell, BA2, Bonnie N Dittel, PhD1,3 and Ahmed Z Obeidat, MD, PhD2, (1)Versiti Blood Research Institute, Milwaukee, WI, (2)Neurology, Medical College of Wisconsin, Milwaukee, WI, (3)Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI

2023 DMX01 Platform/Oral Disease Management

Treatment Transitions in Neuromyelitis Optica Spectrum Disorder Increase the Risk for Neurological Harm

Tatum M Moog, B.S., Alexander D Smith, B.S., Katy W Burgess, PA-C, Morgan McCreary, PhD and Darin T Okuda, MD, Neurology, UT Southwestern Medical Center, Dallas, TX

2023 DMX02 Platform/Oral Disease Management

Randomized, Controlled Trial of Low-Fat Diet for Fatigue in Multiple Sclerosis

Emma Chase, MS1,2, Michael A Lane, MD2,3, Priya Srikanth, MS4, Lindsey Wooliscroft, MD, MCR5,6, Elizabeth Silbermann, MD2,4, Vicky Chen, MD2,4, Kayla Martin, MD2,4, Christopher Hollen, MD2,4, Claire Adams, MS4, Carly Vong, MPH4, Anna Orban, BS4, Allison Fryman, MPH2, Jessica Rice, MD2,4, Angela Horgan, PhD7, Akram Khan, MD7 and Vijayshree Yadav, MD2,4, (1)Neurology, Oregon Health & Science University, Portand, OR, (2)VA Portland Health Care System, Portland, OR, (3)Neurology, Oregon Health & Science University, Porltand, OR, (4)Neurology, Oregon Health & Science University, Portland, OR, (5)Department of Neurology, Oregon Health & Science University, Portland, OR, (6)MS Center of Excellence, VA Portland Health Care System, Portland, OR, (7)Oregon Health & Science University, Portland, OR

2023 DMX03 Platform/Oral Disease Management

Wearables for the Bladder: Stakeholders Perspectives on Moving MS Bladder Dysfunction into the 21st Century

Valerie J Block, PT, DPTSc, Physical Therapy and Rehabilitation Science, University of California San Francisco, San Francisco, CA; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, Anne M Suskind, MD, FACS, MS, Urology, University of California San Francisco, San Francisco, CA and Riley Bove, MD, Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA

2023 DMX04 Platform/Oral Disease Management

Latinx with Multiple Sclerosis Have an Earlier Onset

Farren B.S. Briggs, PhD, ScM1, Tucker Harvey, MS2, Kathryn C. Fitzgerald, ScD3, Ellen M Mowry, MD, MCR3, Jeffrey A. Cohen, MD4 and Daniel Ontaneda, MD PhD4, (1)Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, (2)Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, (3)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (4)Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH

2023 DMX05 Platform/Oral Disease Management

A New Mechanism-Driven Framework to Define Progression in MS – a Proposal from the International Advisory Committee on Clinical Trials in MS

Jennifer Graves, MD PhD MAS, University of California San Diego, San Diego, CA, Tanja Kuhlmann, MD, University Hospital Münster, Münster, Germany, Marcello Moccia, MD, Federico II University of Naples, Naples, Italy, Timothy Coetzee, PhD, National MS Society, New York, NY, Jeffrey A. Cohen, MD, Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, Jorge Correale, MD, FLENI Institute, Buenos Aires, Argentina, Ruth Ann Marrie, MD, PhD, FRCPC, University of Manitoba, Winnipeg, MB, Canada, V. Wee Yong, PhD, University of Calgary, Calgary, AB, Canada, Xavier Montalban, MD PhD, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain, Alan J Thompson, MD, University College London, London, United Kingdom, Daniel S. Reich, MD, PhD, National Institute of Neurological Disorders and Stroke, Bethesda, MD and the International Advisory Committee on Clinical Trials in MS

2023 DMX06 Platform/Oral Disease Management

Longitudinal Associations between Physical Activity and Structural Visual Metrics in Pediatric Acquired Demyelinating Syndromes

Nahid Iseyas, MD Candidate, Temerty Faculty of Medicine, The University of Toronto, Toronto, ON, Canada, Samantha Stephens, PhD, Department of Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON, Canada and Ann Yeh, M.D., Dept. of Paediatrics, Div. of Neurology, The Hospital for Sick Children, Toronto, ON, Canada

2023 IMG01 Platform/Oral Imaging

Progressive Steps Towards a Standardized MRI Protocol for People with Multiple Sclerosis in British Columbia

David KB Li, MD FRCPC1, Samuel Yim, MHA2, Laura Barlow, RTR, RMTR3, Monty Martin, MD FRCPC4, Carolyn Rudden, BSc MA5, June Halper, MSN, APN-C, MSCN, FAAN6, Lori Saslow, MS6 and Anthony Traboulsee, MD7, (1)Radiology and Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada, (2)Vancouver Coastal Health, Vancouver, BC, Canada, (3)UBC MRI Research Centre, Vancouver, BC, Canada, (4)Radiology, University of British Columbia, Vancouver, BC, Canada, (5)British Columbia Ministry of Health, Victoria, BC, Canada, (6)Consortium of Multiple Sclerosis Centers, Hackensack, NJ, (7)University of British Columbia, Vancouver, BC, Canada

2023 IMG02 Platform/Oral Imaging

Spinal Cord Measurement in Super-Resolved Clinical MRI

Blake E Dewey, PhD, Nicole Bou Rjeily, MD, Chen Hu, MS, Christy Hulett, BA, Gabriella Dagher, BS, Alexandra Zambriczki Lee, BS, Anna DuVal, BA, MPH, Peter A Calabresi, MD, Kathryn C. Fitzgerald, ScD and Ellen M. Mowry, MD, MCR, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD

2023 IMG03 Platform/Oral Imaging

Relationship between Baseline Cognitive Performance and Brain Volume Outcomes in Patients with Relapsing Multiple Sclerosis in Enlighten: Phase 3b Study of Ozanimod

Robert Zivadinov, MD, PhD1, John DeLuca, PhD2, Jon V. Riolo, MD3, Chun-Yen Cheng, MS3, Sibyl Wray, MD4, Ann Bass, MD5, Edward Fox, MD, PhD, FAAN6, Emily Riser, MD7, Burhan Chaudhry, MD3, Jennifer Reardon, MSN, ANP-BC, CNRN, MSCN3, Diego Silva, MD3 and Robert T. Naismith, MD8, (1)Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, (2)Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers – New Jersey Medical School, Newark, NJ, (3)Bristol Myers Squibb, Princeton, NJ, (4)Hope Neurology MS Center, Knoxville, TN, (5)Neurology Center of San Antonio, San Antonio, TX, (6)Central Texas Neurology Consultants, Round Rock, TX, (7)Alabama Neurology Associates, Birmingham, AL, (8)Department of Neurology, Washington University in St. Louis School of Medicine, St. Louis, MO

2023 IMG04 Platform/Oral Imaging

Robustness of Emergent MS Phenotypes Derived from Multiprotein Serum Biomarker Data

Ati Ghoreyshi, PhD1, Elisa Sheng, PhD1, Ferhan Qureshi, BS1, Tammy Hoyt, MS2 and John Foley, MD3, (1)Octave Bioscience, Menlo Park, CA, (2)Rocky Mountain MS Research Group, Salt Lake City, UT, (3)Rocky Mountain MS Clinic, Salt Lake City, UT

2023 IMG05 Platform/Oral Imaging

Inconsistent MR Acquisition in Longitudinal Volumetric Analysis: Impacts and Solutions

Lianrui Zuo, MSE1,2, Savannah P Hays, BS1, Blake E Dewey, PhD3, Samuel W Remedios, BS4,5, Yuan Xue, PhD1, Sandra D Cassard, ScD3, Carolyn Koch, MA3, Ann Fishman, MBA6, Aaron Carass, MS1, Jerry L Prince, PhD1, Ellen M. Mowry, MD, MCR3 and Scott D Newsome, DO, MSCS3, (1)Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, (2)National Institute on Aging, National Institutes of Health, Baltimore, MD, (3)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (4)Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, (5)Computer Science, Johns Hopkins University, Baltimore, MD, (6)Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD

2023 IMG06 Platform/Oral Imaging

An Unblinded Observational Study of Mindfulness-Based Stress Reduction in MS: MRI and Biological Inflammatory Correlates of Patient-Reported Outcomes

Christopher C Hemond, MD1, Mugdha Deshpande, MS1, Idanis Berrios-Morales, MD1, George M Slavich, PhD2 and Steven W Cole, PhD2, (1)Neurology, University of Massachusetts, Worcester, MA, (2)Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA

2023 PSY01 Platform/Oral Psychosocial

The Impact of a 4-Session Stress Management Protocol on Mood and Physiological Measures of Stress Using Biofeedback in MS Patients

Amy Sullivan, Psy.D.1, Alexa Kane, PsyD1, Grace E Tworek, Psy.D.1 and Tucker Harvey, MS2, (1)The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, (2)Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

2023 PSY02 Platform/Oral Psychosocial

Financial Stress, Job Insecurity, and Social Isolation in People with MS during the COVID-19 Pandemic: Impact on Depression Severity and Suicidal Ideation

Avery Largent, BA1, Odelin Charron, MSc, MSE1, Diana Andino, MD1, Amanda Montague, EdM2, Alexis Crispino, BA2, Joseph Wozny, MPH3, Trudy Millard Krause, DrPH, MS3, Ethan Meltzer, MD1, Ethan Huson, BSA Neuroscience1 and Leorah Freeman, MD, PhD1, (1)Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, (2)Multiple Sclerosis Association of America, Cherry Hill, NJ, (3)Center for Healthcare Data, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX

2023 PSY03 Platform/Oral Psychosocial

Vascular Function and Cognition in Persons with Multiple Sclerosis: Preliminary Examination

Peixuan Zheng, PhD1, Lara A. Pilutti, PhD2,3, Noah G. DuBose, MS1 and Robert W. Motl, PhD1, (1)Kinesiology and Nutrition, University of Illinois Chicago, Chicago, IL, (2)Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada, (3)Brain and Mind Research Institute, University of Ottawa, Ottawa, ON, Canada

2023 PSY04 Platform/Oral Psychosocial

Physical Activity and Social Cognitive Theory Variables Among Anxious Persons with Multiple Sclerosis

Petra Silic, BS1, Brenda Jeng, PhD1, Catherine D Jones, MSPH2, Trinh Huynh, MPH2, Jennifer Duffecy, PhD3 and Robert W. Motl, PhD1, (1)Kinesiology and Nutrition, University of Illinois Chicago, Chicago, IL, (2)Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (3)Psychiatry, University of Illinois Chicago, Chicago, IL

2023 PSY05 Platform/Oral Psychosocial

The Role of Social Work in Pediatric Multiple Sclerosis Centers: Reviewing Rates of Depression and Suicidality in Pediatric Patients

Sarah C Stoney, MSW, LSW1, Chelsea C Black, Ph.D., ABPP-CN2, Isabella Sobejano, (BA expected completion May 2024)1, Elizabeth Kunzelman, BSN, RN1, Amy T Waldman, M.D., M.S.C.E.1, Sarah E Hopkins, MD, MSPH3, Sona Narula, M.D.1 and Brenda Banwell, MD, FRCPC, FAAN4, (1)Neurology, The Children’s Hospital of Philadelphia, Philadelphia, PA, (2)Neuropsychology, The Children’s Hospital of Philadelphia, Philadelphia, PA, (3)Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA, (4)The Children’s Hospital of Philadelphia, Philadelphia, PA

2023 PSY06 Platform/Oral Psychosocial

Changes in MS Patients Behaviors during the COVID-19 Pandemic

Tymon Krzywinski, BA, Washington University in St. Louis, Saint Louis, MO and Salim Chahin, MD, MSCE, Department of Neurology, Washington University in St. Louis, St. Louis, MO

2023 REH01 Platform/Oral Rehabilitation

Alexa, How Can I Manage My MS? Using Speech Recognition Technology to Optimize Accessible Communication, Health Literacy, and Environmental Control

Alexander Burnham, MS, CCC-SLP, MSCS, Communication Sciences and Disorders, Emerson College, Boston, MA

2023 REH02 Platform/Oral Rehabilitation

Surprisingly Large Differences in the Long-Term Effects of Multidisciplinary Neurorehabilitation Depending on Rehabilitation Goals: Casting Light into the “Black Box” of Rehabilitation – the Danish MS Hospitals Rehabilitation Study.

Finn Boesen, MD1, Michael Norgaard, MSc1, Anders G Skjerbaek, MRSc1, Thor Petersen, DMSc2, Peter V Rasmussen, Phd3 and Philipp Trénel, Phd4, (1)The Danish MS Hospitals, Haslev and Ry, Denmark, (2)University of Southern Denmark, Odense, Denmark, (3)Aarhus University Hospital, Aarhus, Denmark, (4)Danish Technological Institute, Aarhus, Denmark

2023 REH03 Platform/Oral Rehabilitation

Blood Flow Restriction in People with Advanced Multiple Sclerosis: “Now I Have a Sliver of Hope That I Might be Able to Build Some Strength”

Laura A Swink, PhD, OTR/L1,2,3, Wesley Thornton, DPT2, Kathryn A Nearing, PhD, MA1,2, Mark M Manago, PT, PhD1,2,4 and University of Colorado, (1)Eastern Colorado Geriatric Research Education and Clinical Center (GRECC), Veterans Administration, Aurora, CO, (2)Department of Physical Medicine and Rehabilitation, University of Colorado Anschutz Medical Campus, Aurora, CO, (3)Research, Veterans Administration, Aurora, CO, (4)Department of Neurology, University of Colorado School of Medicine, Aurora, CO

2023 REH04 Platform/Oral Rehabilitation

Physical Activity Together for Multiple Sclerosis (PAT-MS): Preliminary Results of a Randomized Controlled Feasibility Trial

Afolasade Fakolade, PhD1, Zain Awadia, MSc2, Odessa J. McKenna, MSc3, Katherine L. Cardwell, BHSc4, Taylor Hume, BHSc4, Julia Ludgate, BHSc5, Mark S Freedman, MSc, MD6, Marcia Finlayson, PhD1, Amy Latimer-Cheung, PhD7 and Lara A. Pilutti, PhD8, (1)School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada, (2)Faculty of Health Sciences, McMaster University, Ottawa, ON, Canada, (3)Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada, (4)Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada, (5)Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada, (6)Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada, (7)School of Kinesiology and Health Studies, Queen’s University, Kingston, ON, Canada, (8)Brain and Mind Research Institute, University of Ottawa, Ottawa, ON, Canada

2023 REH05 Platform/Oral Rehabilitation

Impact of Occupational Performance Coaching Among Adults with MS

Marcia Finlayson, PhD, Niloufar Malakouti, MSc, Martina Franz, MSc, Dorothy Kessler, PhD and Afolasade Fakolade, PhD, School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada

2023 REH06 Platform/Oral Rehabilitation

Physical Activity Levels in Multiple Sclerosis: An Updated Systematic Review and Quantitative Synthesis

Brenda Jeng, PhD, Noah G. DuBose, MS, Trevor B. Martin, BS, Petra Silic, BS, Victoria A. Flores, PhD, Peixuan Zheng, PhD and Robert W. Motl, PhD, Kinesiology and Nutrition, University of Illinois Chicago, Chicago, IL

2023 CAM03 Poster Complementary and alternative therapies

Initial Assessment of Experience and Outcomes of an Online Mindfulness-Based Stress Reduction (MBSR) Pilot Program for People with Multiple Sclerosis.

Brant J. Oliver, PhD, MS, MPH, APRN-BC, Community of Family and Medicine, Dartmouth Health, Lebanon, NH, Nivethitha Manohar, MPH, Paul L. Foster School of Medicine, Texas Tech University, Al Paso, TX, Jackson Cabot, NA, University of New Hampshire, Durham, NH, Ann Cabot, DO, Multidisciplinary Multiple Sclerosis Clinic at Concord Hospital, Concord, NH and Jeanne Ann Whittington, NA, Multiple Sclerosis Specialty Care Program, Concord Hospital, Concord, NH

2023 CAM04 Poster Complementary and alternative therapies

Perceptions of People with Multiple Sclerosis Who Practice Qigong or Tai Chi: A Qualitative Study Using Focus Groups

Lita P Buttolph, PhD, DSOM1, Jamie Villanueva, DAOM2, Heena R Manglani, PhD3,4, Tanya Snyder, BS1, Lindsey Wooliscroft, MD, MCR5,6, Gloria Y Yeh, MD, MPH4,7, Ryan Bradley, ND, MPH1 and Heather Zwickey, PhD1, (1)Helfgott Research Institute, National University of Natural Medicine, Portland, OR, (2)School of Nursing, University of Washington, Seattle, WA, (3)Center for Health Outcomes and Interdisciplinary Research, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, (4)Osher Center for Integrative Medicine, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA, (5)MS Center of Excellence, VA Portland Health Care System, Portland, OR, (6)Department of Neurology, Oregon Health & Science University, Portland, OR, (7)Division of General Medicine, Beth Deaconess Medical Center, Harvard Medical School, Boston, MA

2023 CAM05 Poster Complementary and alternative therapies

Evaluation of an Online Wellness Course for the Adoption of Healthy Lifestyle Behaviors Among People with Multiple Sclerosis: A Randomized Waitlist-Control Trial

Tyler J. Titcomb, PhD, RDN1, Max Sherwood, BS1, Mary Ehlinger, BS1, Solange M. Saxby, PhD, RDN1, Farnoosh Shemirani, PhD1, Patrick Ten Eyck, PhD2, Linda G. Snetselaar, PhD, RDN3 and Terry L. Wahls, MD1, (1)Internal Medicine, University of Iowa, Iowa City, IA, (2)Institute for Clinical and Translational Science, University of Iowa, Iowa City, IA, (3)Epidemiology, University of Iowa, Iowa City, IA

2023 CAM06 Poster Complementary and alternative therapies

Therapeutic Diet and Lifestyle Vs. Disease-Modifying Therapies for Relapsing-Remitting MS and Clinically Isolated Syndrome: A Quasi-Experimental Study

Solange M. Saxby, PhD, RDN1, Tyler J. Titcomb, PhD, RDN1, Farnoosh Shemirani, PhD1, Mary Ehlinger, BS1, Lisa Brooks, MA, RDN1, Linda G. Snetselaar, PhD, RDN2 and Terry L. Wahls, MD1, (1)Internal Medicine, University of Iowa, Iowa City, IA, (2)Epidemiology, University of Iowa, Iowa City, IA

2023 CSR01 Poster Case Reports/Case Series

Longitudinally Extensive Transverse Myelitis Is Not Always What It Seems; An Uncommon and Hidden Perpetrator

Alexandra C Simpson, MD, MA and Scott D Newsome, DO, MSCS, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD

2023 CSR02 Poster Case Reports/Case Series

Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Mimics Multiple Sclerosis (MS) or Other Adult-Onset Leukodystrophies

Andreas Meier, MD, Clinical Development, Vigil Neuroscience, Watertown, MA, Leslie Leahy, PhD, Boston, MA, Cynthia Cassandro, BS, RN, Patient Engagement, Vigil Neuroscience, Watertown, MA and Spyros Papapetropoulos, MD, PhD, Clinical Development, Vigil Neuroscience (Former Employee), Watertown, MA

2023 CSR03 Poster Case Reports/Case Series

Myelin Oligodendrocyte Glycoprotein Antibody Disease in a Woman with Invasive Ductal Carcinoma

Cecelia A Barry, B.A., University of Illinois College of Medicine, Chicago, IL, Evan Jameyfield, M.D., The University of Illinois at Chicago Department of Neurology and Rehabilitation, University of Illinois Hospital & Health Sciences System, Chicago, IL and Jeffrey Loeb, M.D., Ph.D, Department of Neurology and Rehabilitation, University of Illinois at Chicago, Chicago, IL

2023 CSR04 Poster Case Reports/Case Series

Satralizumab Treatment in Adult Patients with AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder: A Case Series

Hesham Abboud, MD, PhD1, Brian Steingo, MD2, Diana Vargas, MD3, Julie J Patel, PharmD, BCACP3,4, Nancy Nealon, MD5, Mary Alissa Willis, MD6, Yang Mao-Draayer, MD, PhD7, Dmitry Khaitov, MD8, Jose Avila Ornelas, MD9, Adnan Subei, DO10, Clifford Reed, MD11, Lisa Ferayorni, MD12, Xavier Laucirica, MD12 and Shervin Gholizadeh, PhD12, (1)Multiple Sclerosis and Neuroimmunology Program, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, (2)Infinity Clinical Research, Sunrise, FL, (3)Department of Neurology, Emory University School of Medicine, Atlanta, GA, (4)Department of Pharmacy, Emory University Hospital Midtown, Atlanta, GA, (5)Department of Neurology, Weill Cornell Medicine, New York, NY, (6)Department of Neurology, University of Mississippi Medical Center, Jackson, MS, (7)Department of Neurology, University of Michigan School of Medicine, Ann Arbor, MI, (8)Lehigh Valley Health Network, Allentown, PA, (9)HIMA Caguas Multiple Sclerosis Center, Caguas, Puerto Rico, (10)Department of Neurology, Memorial Healthcare System, Hollywood, FL, (11)Department of Neurology, Reading Hospital, West Reading, PA, (12)Genentech, Inc., South San Francisco, CA

2023 CSR06 Poster Case Reports/Case Series

Multiple Sclerosis and Schizophrenia, Is Epstein Barr Virus a Possible Immune Trigger for These Chronic Conditions?

Mirla Avila, MD, Neurology, Texas Tech University Health Sciences Center, Lubbock, TX, Mirla Nicole Martinez, student, Texas Tech, Lubbock, TX and Texas Tech

2023 CSR07 Poster Case Reports/Case Series

Use of COVID-19 Prevention Therapy Tixagevimab and Cilgavimab (Evusheld) in Patients with Multiple Sclerosis: A Single Center Experience

Petra Brayo, MD1, Amy Safadi, MD1, In Guk (Josh) Kang, BS2, Rebecca Kumar, MD3, Bethany Schreiber, NP1 and Carlo Tornatore, MD1, (1)Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, (2)Georgetown University School of Medicine, Washington, DC, (3)Department of Infectious Diseases, MedStar Georgetown University Hospital, Washigton, DC